Search
Cartesian Therapeutics Inc
RNACAdd to Watchlist
10.590USD
+0.410+4.03%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
275.38MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Cartesian Therapeutics Inc is 8.75, ranking 63 out of 387 in the Biotechnology & Medical Research industry. The average price target is 39.00, with a high of 44.00 and a low of 16.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
33.833
Target Price
+232.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Cartesian Therapeutics Inc
RNAC
8
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Cartesian Therapeutics Inc's expected revenue for the next quarter?
Cartesian Therapeutics Inc's expected revenue is 134.75K.
What is Cartesian Therapeutics Inc's price target?
Analysts forecast that Cartesian Therapeutics Inc's price target is USD 39.00, with the highest forecast at USD 44.00 and the lowest forecast at USD 16.00.
How have Cartesian Therapeutics IncRNAC's recent earnings per share performed?
The market expectation was USD -1.46, while Cartesian Therapeutics IncRNAC's earnings per share (EPS) for the previous quarter was USD -3.56. EPS for the next quarter is expected at USD -0.87.
What is the analyst rating for Cartesian Therapeutics Inc?
Based on the ratings of Cartesian Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.